Great Lakes Advisors LLC Has $16.26 Million Position in Eli Lilly and Company $LLY

Great Lakes Advisors LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 10.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,303 shares of the company’s stock after selling 2,470 shares during the period. Great Lakes Advisors LLC’s holdings in Eli Lilly and Company were worth $16,255,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in LLY. Laurel Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $8,827,714,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the period. Franklin Resources Inc. raised its stake in Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after buying an additional 536,679 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.0%

Shares of Eli Lilly and Company stock opened at $1,023.81 on Friday. The stock has a market capitalization of $967.89 billion, a PE ratio of 50.09, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The stock has a 50 day moving average price of $1,057.27 and a two-hundred day moving average price of $887.02. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a potential $1.93 billion deal with Repertoire Immune Medicines to develop autoimmune therapies, expanding its pipeline in high‑value immune diseases and adding near‑ and mid‑term development optionality. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Lilly agreed to a collaboration/option deal with gene‑editing firm Seamless (up to $1.12B) targeting hearing‑loss programs—diversifies R&D and signals commitment to next‑gen modalities. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — a boost for supply-chain resilience, potential capacity for GLP‑1 and other biologics, and a politically favorable narrative. Trump says Eli Lilly to build six US plants
• Positive Sentiment: Analysts/coverage point to strong Q4 fundamentals, oncology pipeline momentum and an AI partnership (Nvidia) positioning Lilly for R&D acceleration—supportive for earnings and longer‑term growth expectations. Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Positive Sentiment: A Seeking Alpha take argues Lilly’s obesity‑pricing tradeoffs (access vs. price) are a net positive, supporting adoption and sales momentum for GLP‑1/obesity launches. Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
• Neutral Sentiment: Wall Street expects continued earnings strength and a likely beat in the upcoming report based on Lilly’s recent surprise history—this can support sentiment if results meet/beat. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Coverage pieces and bullish theses reiterate Lilly’s secular GLP‑1/oncology story but note valuation is rich—supports conviction but increases sensitivity to execution. Eli Lilly and Company (LLY): A Bull Case Theory
• Negative Sentiment: Competitive pressure: Novo Nordisk is outspending Lilly on U.S. GLP‑1 advertising by a wide margin, which could pressure market share and marketing efficiency. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Policy risk: Medicare’s expanded negotiation list includes Lilly’s Verzenio, introducing potential pricing pressure for certain oncology revenues if negotiations lead to cuts. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Market reaction: some coverage notes shares dipped after the gene‑editing tie‑up, illustrating sensitivity to deal economics and investor focus on near‑term margins versus long‑term optionality. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. Wolfe Research increased their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, January 14th. Truist Financial raised their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. UBS Group initiated coverage on Eli Lilly and Company in a research note on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 price target on the stock. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Buy” and an average target price of $1,173.91.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.